Preclinical assessment of an anti-HTLV-1 heterologous DNA/MVA vaccine protocol expressing a multiepitope HBZ protein

Preclinical assessment of an anti-HTLV-1 heterologous DNA/MVA vaccine protocol expressing a multiepitope HBZ protein

Abstract Background Human T-lymphotropic virus 1 (HTLV-1) is associated with the development of several pathologies and chronic infection in humans. The inefficiency of the available treatments and the challenge in developing a protective vaccine highlight the need to produce effective immunotherape...

Full description

Bibliographic Details
Main Authors: D. S. O. Daian e Silva, L. J. Cox, A. S. Rocha, Á. Lopes-Ribeiro, J. P. C. Souza, G. M. Franco, J. L. C. Prado, T. A. Pereira-Santos, M. L. Martins, J. G. A. Coelho-dos-Reis, T. M. Gomes-de-Pinho, F. G. Da Fonseca, E. F. Barbosa-Stancioli
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Virology Journal
Subjects:
Vaccine
Human T-lymphotropic virus 1
HBZ
Recombinant Modified Vaccinia virus Ankara (MVA-HBZ)
Plasmid DNA vaccine (pcDNA3.1(+)-HBZ)
Online Access:https://doi.org/10.1186/s12985-023-02264-z

Internet

https://doi.org/10.1186/s12985-023-02264-z

Similar Items